摘要
目的探讨复方红豆杉胶囊用于非小细胞肺癌术后转移患者挽救化疗后维持治疗的效果。方法选择非小细胞肺癌术后出现转移且完成了4个疗程挽救化疗的患者174例,按治疗意愿分为2组,对照组87例给予姑息对症支持等治疗,治疗组87例在此基础上给予复方红豆杉胶囊维持治疗2～4个疗程(21 d为1个疗程),随访2年。观察2组近期临床疗效及总生存期(OS)、无进展生存时间(PFS)、KPS评分及毒副反应情况。结果治疗组疾病缓解率和疾病控制率分别为17.24%和50.57%,中位OS为17个月,无严重不良反应出现;对照组疾病缓解率和疾病控制率分别为5.75%和21.84%,中位OS为11个月,无不良反应。治疗组的疾病缓解率、疾病控制率明显高于对照组(P均<0.05),OS和PFS明显长于对照组(P均<0.05),入组后2个月和4个月KPS评分明显高于对照组(P均<0.05)。结论复方红豆杉胶囊可以作为非小细胞肺癌术后转移拒绝或不适合其他维持方案患者的维持治疗。
Objective It is to investigate the effect of compound Chinese yew capsule in maintenance therapy after salvage chemotherapy in patients with non-small cell lung cancer after postoperative metastasis. Methods A total of 174 patients with non-small cell lung cancer who underwent metastases after operation and completed 4 courses of salvage chemotherapy were enrolled. According to their treatment willingness, they were divided into treatment group and control group, 87 cases in each group. The control group was given palliative symptomatic support and other treatments. On the basis of this, the treatment group was given 2-4 courses of treatment with compound Chinese yew capsules (21 days for one course of treatment), followed up for 2 years, and the short-term clinical efficacy and overall survival (OS), progression-free survival time (PFS), KPS score and toxic side effects in the two groups were observed. Results The disease remission rate and disease control rate were respectively 17.24% and 50.57% in the treatment group, and the median OS was 17 months, no serious adverse reactions occurred. The disease remission rate and disease control rate in the control group were respectively 5.75% and 21.84%, the median OS was 11 months with no adverse reactions. The disease remission rate and disease control rate of the treatment group were significantly higher, the OS and PFS were significantly longer, and the KPS scores at 2 and 4 months after enrollment were significantly higher than those of the control group ( P <0.05). Conclusion Compound Chinese yew capsule can be used as maintenance medicine for patients with non-small cell lung cancer after postoperative metastasis who refuse or not suitable for other maintenance programs.
作者
蔡华荣
张海梅
CAI Huarong;ZHANG Haimei(Affiliated Tumor Hospital of Chongqing University, Chongqing Cancer Institute, Chongqing Tumor Hospital, Chongqing 400030, China)
出处
《现代中西医结合杂志》
CAS
2019年第15期1618-1621,1651,共5页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
非小细胞肺癌
维持治疗
复方红豆杉胶囊
non-small cell lung cancer
maintenance therapy
compound yew capsule
作者简介
蔡华荣,男,硕士,副主任医师,擅长肺癌、食管癌的手术治疗及晚期肺癌的综合治疗;通信作者:张海梅,E-mail:18555203@qq.com.
